BriaCell Historical Income Statement

BCTXW Stock

USD 0.43 0.08 22.86%

Historical analysis of BriaCell Therapeutics income statement accounts such as Interest Expense of 0.0, Other Operating Expenses of 35 M or Total Operating Expenses of 35 M can show how well BriaCell Therapeutics Corp performed in making a profits. Evaluating BriaCell Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of BriaCell Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining BriaCell Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BriaCell Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BriaCell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

About BriaCell Income Statement Analysis

BriaCell Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to BriaCell Therapeutics shareholders. The income statement also shows BriaCell investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

BriaCell Therapeutics Income Statement Chart

At this time, BriaCell Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Other Operating Expenses is likely to climb to about 35 M in 2024, whereas Operating Income is likely to drop (5 M) in 2024.

Other Operating Expenses Selling General Administrative Research Development Cost Of Revenue

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of BriaCell Therapeutics. It is also known as BriaCell Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on BriaCell Therapeutics income statement and represents the costs associated with goods and services BriaCell Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most accounts from BriaCell Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into BriaCell Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BriaCell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

	2021	2022	2023	2024 (projected)
Interest Income	136.7K	891.2K	1.0M	1.1M
Research Development	8.0M	15.3M	27.2M	28.5M

Interest Income Research Development

BriaCell Therapeutics income statement Correlations

	Depreciation And Amortization	Interest Expense	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Research Development	Interest Income	Net Interest Income	Net Income From Continuing Ops	Reconciled Depreciation	Gross Profit	Cost Of Revenue
Depreciation And Amortization		0.0	0.58	-0.59	-0.56	-0.37	0.49	-0.2	0.37	-0.2	-0.13	0.73	0.67	0.58	-0.17	-0.63	0.97	-0.4	0.63
Interest Expense	0.0		-0.45	0.26	0.62	0.54	-0.55	0.61	-0.59	0.61	0.41	-0.41	-0.5	-0.51	0.18	0.59	0.06	-0.09	-0.31
Other Operating Expenses	0.58	-0.45		-0.36	-0.87	-0.49	0.99	-0.41	0.51	-0.41	-0.22	0.73	0.97	0.99	0.27	-0.61	0.44	-0.17	0.88
Operating Income	-0.59	0.26	-0.36		0.65	0.88	-0.34	0.78	-0.41	0.78	0.15	-0.82	-0.4	-0.46	0.38	0.75	-0.53	0.77	-0.36
Ebit	-0.56	0.62	-0.87	0.65		0.83	-0.89	0.66	-0.78	0.66	0.48	-0.88	-0.89	-0.92	0.11	0.86	-0.43	0.32	-0.78
Ebitda	-0.37	0.54	-0.49	0.88	0.83		-0.52	0.82	-0.71	0.82	0.49	-0.78	-0.51	-0.6	0.28	0.79	-0.3	0.54	-0.39
Total Operating Expenses	0.49	-0.55	0.99	-0.34	-0.89	-0.52		-0.47	0.57	-0.47	-0.29	0.71	0.96	0.99	0.24	-0.64	0.35	-0.1	0.84
Income Before Tax	-0.2	0.61	-0.41	0.78	0.66	0.82	-0.47		-0.36	1.0	0.07	-0.68	-0.42	-0.53	0.29	0.73	-0.1	0.47	-0.31
Total Other Income Expense Net	0.37	-0.59	0.51	-0.41	-0.78	-0.71	0.57	-0.36		-0.36	-0.9	0.54	0.61	0.58	-0.25	-0.72	0.34	0.04	0.39
Net Income	-0.2	0.61	-0.41	0.78	0.66	0.82	-0.47	1.0	-0.36		0.07	-0.68	-0.42	-0.53	0.29	0.73	-0.1	0.47	-0.31
Income Tax Expense	-0.13	0.41	-0.22	0.15	0.48	0.49	-0.29	0.07	-0.9	0.07		-0.16	-0.29	-0.27	0.08	0.36	-0.17	-0.27	-0.05
Selling General Administrative	0.73	-0.41	0.73	-0.82	-0.88	-0.78	0.71	-0.68	0.54	-0.68	-0.16		0.79	0.79	-0.35	-0.91	0.6	-0.64	0.77
Research Development	0.67	-0.5	0.97	-0.4	-0.89	-0.51	0.96	-0.42	0.61	-0.42	-0.29	0.79		0.97	0.05	-0.74	0.54	-0.16	0.9
Interest Income	0.58	-0.51	0.99	-0.46	-0.92	-0.6	0.99	-0.53	0.58	-0.53	-0.27	0.79	0.97		0.18	-0.71	0.45	-0.21	0.85
Net Interest Income	-0.17	0.18	0.27	0.38	0.11	0.28	0.24	0.29	-0.25	0.29	0.08	-0.35	0.05	0.18		0.54	-0.15	0.32	0.02
Net Income From Continuing Ops	-0.63	0.59	-0.61	0.75	0.86	0.79	-0.64	0.73	-0.72	0.73	0.36	-0.91	-0.74	-0.71	0.54		-0.53	0.4	-0.64
Reconciled Depreciation	0.97	0.06	0.44	-0.53	-0.43	-0.3	0.35	-0.1	0.34	-0.1	-0.17	0.6	0.54	0.45	-0.15	-0.53		-0.31	0.49
Gross Profit	-0.4	-0.09	-0.17	0.77	0.32	0.54	-0.1	0.47	0.04	0.47	-0.27	-0.64	-0.16	-0.21	0.32	0.4	-0.31		-0.26
Cost Of Revenue	0.63	-0.31	0.88	-0.36	-0.78	-0.39	0.84	-0.31	0.39	-0.31	-0.05	0.77	0.9	0.85	0.02	-0.64	0.49	-0.26

Click cells to compare fundamentals

BriaCell Therapeutics Account Relationship Matchups

BriaCell Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	15.3K	15.3K	15.3K	15.3K	17.6K	18.4K
Interest Expense	15.6K	23.8K	27.0K	46.1K	979.0	0.0
Other Operating Expenses	1.4M	3.7M	3.4K	23.3M	33.3M	35.0M
Operating Income	(3.6M)	(7.0M)	(15.3M)	(23.3M)	(4.8M)	(5.0M)
Ebit	1.4M	3.7M	(11.5M)	(22.4M)	(20.1M)	(19.1M)
Ebitda	1.4M	3.7M	(11.5M)	(22.4M)	(4.8M)	(4.6M)
Total Operating Expenses	(1.4M)	(3.7M)	(3.4K)	23.3M	33.3M	35.0M
Income Before Tax	1.4M	3.7M	(11.5M)	(20.3M)	(4.8M)	(4.6M)
Total Other Income Expense Net	(72.3K)	(6.8M)	3.7M	3.0M	3.4M	3.6M
Net Income	1.4M	3.7M	(11.5M)	(20.3M)	(4.8M)	(4.6M)
Income Tax Expense	(72.3K)	6.6M	979.0	(152.6K)	(175.5K)	(166.7K)
Selling General Administrative	1.4M	3.7M	7.3M	7.9M	6.2M	6.5M
Research Development	2.2M	1.3M	8.0M	15.3M	27.2M	28.5M
Interest Income	54.0K	3.1K	136.7K	891.2K	1.0M	1.1M
Net Interest Income	(36.2K)	(42.9K)	(11.5M)	891.2K	802.1K	842.2K
Net Income From Continuing Ops	(4.9M)	(428.3K)	(26.8M)	(20.3M)	(18.3M)	(17.4M)
Reconciled Depreciation	18.7K	15.3K	15.3K	15.3K	17.6K	15.8K
Gross Profit	(14.0K)	(15.6K)	(15.1K)	(15.5K)	(14.0K)	(14.7K)
Cost Of Revenue	14.0K	15.6K	15.1K	15.5K	17.9K	16.4K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for BriaCell Stock Analysis

When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BriaCell Historical Income Statement

About BriaCell Income Statement Analysis

BriaCell Therapeutics Income Statement Chart

Other Operating Expenses

Cost Of Revenue

BriaCell Therapeutics income statement Correlations

BriaCell Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BriaCell Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for BriaCell Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Income	+ 1.0	Income Before Tax
Total Operating Expenses	+ 0.99	Other Operating Expenses
Interest Income	+ 0.99	Other Operating Expenses
Interest Income	+ 0.99	Total Operating Expenses
Reconciled Depreciation	+ 0.97	Depreciation And Amortization
Research Development	+ 0.97	Other Operating Expenses

Interest Income	- 0.92	Ebit
Net Income From Continuing Ops	- 0.91	Selling General Administrative
Income Tax Expense	- 0.9	Total Other Income Expense Net
Research Development	- 0.89	Ebit
Total Operating Expenses	- 0.89	Ebit
Selling General Administrative	- 0.88	Ebit